Literature DB >> 10977390

Testing the validity of cost-effectiveness models.

C McCabe1, S Dixon.   

Abstract

A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due to the alleged arbitrary nature of their construction. This has led researchers to try and identify ways of improving the quality of cost-effectiveness models through identifying 'best practice', producing guidelines for peer review and identifying tests of validity. This paper investigates the issue of testing the validity of cost-effectiveness models or, perhaps more appropriately, whether it is possible to objectively measure the quality of a cost-effectiveness model. A review of the literature shows that there is much confusion over the different aspects of modelling that should be assessed in respect to model quality, and how this should be done. We develop a framework for assessing model quality in terms of: (i) the structure of the model; (ii) the inputs of the model; (iii) the results of the model; and (iv) the value of the model to the decision maker. Quality assessment is investigated within this framework, and it is argued that it is doubtful that a set of objective tests of validity will ever be produced, or indeed that such an approach would be desirable. The lack of any clearly definable and objective tests of validity means that the other parts of the evaluation process need to be given greater emphasis. Quality assurance forms a small part of a broader process and is best implemented in the form of good practice guidelines. A set of key guidelines are presented.

Mesh:

Year:  2000        PMID: 10977390     DOI: 10.2165/00019053-200017050-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  26 in total

Review 1.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 2.  The use of QALY and non-QALY measures of health-related quality of life. Assessing the state of the art.

Authors:  M Deverill; J Brazier; C Green; A Booth
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 4.  The clinical-economic trial: promise, problems, and challenges.

Authors:  N R Powe; R I Griffiths
Journal:  Control Clin Trials       Date:  1995-12

5.  Problems of using modelling in the economic evaluation of health care.

Authors:  T A Sheldon
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

7.  Can resource use be extracted from randomized controlled trials to calculate costs? A review of smoking cessation interventions in general practice.

Authors:  K Rigby; C Silagy; A Crockett
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

Review 8.  Economic analysis alongside clinical trials: problems and potential.

Authors:  M Drummond
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

9.  Economic evaluation and quality of life assessments in cancer clinical trials: the CHART Trial.

Authors:  J Morris; M Goddard
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Toward a peer review process for medical decision analysis models.

Authors:  F A Sonnenberg; M S Roberts; J Tsevat; J B Wong; M Barry; D L Kent
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

View more
  24 in total

1.  Adding specialized clinics for remote-dwellers with chronic kidney disease: a cost-utility analysis.

Authors:  Natasha Wiebe; Scott W Klarenbach; Betty Chui; Bharati Ayyalasomayajula; Brenda R Hemmelgarn; Kailash Jindal; Braden Manns; Marcello Tonelli
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Anthony O'Hagan; Christopher McCabe; Ron Akehurst; Alan Brennan; Andrew Briggs; Karl Claxton; Elisabeth Fenwick; Dennis Fryback; Mark Sculpher; David Spiegelhalter; Andrew Willan
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Authors:  Zoë Philips; Laura Bojke; Mark Sculpher; Karl Claxton; Su Golder
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

Review 6.  Is evidence sufficient for evidence-based medicine?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

7.  Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings.

Authors:  April D Kimmel; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  Med Decis Making       Date:  2014-10-20       Impact factor: 2.583

8.  Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study.

Authors:  Samantha Husbands; Susan Jowett; Pelham Barton; Joanna Coast
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

Review 9.  Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.

Authors:  Ava John-Baptiste; Man Wah Yeung; Victoria Leung; Gabrielle van der Velde; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

Review 10.  Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

Authors:  Sanjib Saha; Ulf-G Gerdtham; Pia Johansson
Journal:  Int J Environ Res Public Health       Date:  2010-08-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.